{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:24:49Z","timestamp":1780611889488,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1F1A1074876"],"award-info":[{"award-number":["NRF-2022R1F1A1074876"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-88048-7","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T16:08:34Z","timestamp":1738685314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical and microbiological analysis of risk factors for breakthrough bloodstream infection during Tigecycline Therapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Sol","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heungsup","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Na","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongman","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Oh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Ho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hee","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Pil","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"88048_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.diagmicrobio.2010.05.012","volume":"68","author":"AT Freire","year":"2010","unstructured":"Freire, A. T. et al. Comparison of tigecycline with imipenem\/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 68, 140\u2013151. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2010.05.012 (2010).","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"11","key":"88048_CR2","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1128\/AAC.49.11.4658-4666.2005","volume":"49","author":"J Breedt","year":"2005","unstructured":"Breedt, J. et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 49(11), 4658\u20134666. https:\/\/doi.org\/10.1128\/AAC.49.11.4658-4666.2005 (2005).","journal-title":"Antimicrob Agents Chemother"},{"key":"88048_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/jac\/dkn165","volume":"62","author":"DE Karageorgopoulos","year":"2008","unstructured":"Karageorgopoulos, D. E., Kelesidis, T., Kelesidis, I. & Falagas, M. E. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemotherapy 62, 45\u201355 (2008).","journal-title":"J Antimicrob Chemotherapy"},{"key":"88048_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/0002-9343(76)90328-4","volume":"61","author":"ET Anderson","year":"1976","unstructured":"Anderson, E. T., Young, L. S. & Hewitt, W. L. Simultaneous antibiotic levels in \u201cbreakthrough\u201d gram-negative rod bacteremia. Am J Med 61, 493\u2013497 (1976).","journal-title":"Am J Med"},{"issue":"4","key":"88048_CR5","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/cncr.24812","volume":"116","author":"G Rangaraj","year":"2010","unstructured":"Rangaraj, G., Granwehr, B. P., Jiang, Y., Hachem, R. & Raad, I. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug\u2010resistant organisms. Cancer 116(4), 967\u2013973. https:\/\/doi.org\/10.1002\/cncr.24812 (2010).","journal-title":"Cancer"},{"key":"88048_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ajic.2014.09.022","volume":"43","author":"MH Tsai","year":"2015","unstructured":"Tsai, M. H. et al. Breakthrough bacteremia in the neonatal intensive care unit: incidence, risk factors, and attributable mortality. Am J Infect Control 43, 20\u201325. https:\/\/doi.org\/10.1016\/j.ajic.2014.09.022 (2015).","journal-title":"Am J Infect Control"},{"key":"88048_CR7","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.1128\/AAC.00984-16","volume":"60","author":"JY Lee","year":"2016","unstructured":"Lee, J. Y. et al. Clinical features and risk factors for development of breakthrough gram-negative bacteremia during carbapenem therapy. Antimicrob Agents Chemother 60, 6673\u20136678. https:\/\/doi.org\/10.1128\/AAC.00984-16 (2016).","journal-title":"Antimicrob Agents Chemother"},{"key":"88048_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00931-17","author":"YT Lee","year":"2017","unstructured":"Lee, Y. T. et al. Multicenter study of clinical features of breakthrough acinetobacter bacteremia during carbapenem therapy. Antimicrob Agents Chemother https:\/\/doi.org\/10.1128\/AAC.00931-17 (2017).","journal-title":"Antimicrob Agents Chemother"},{"key":"88048_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","volume":"49","author":"G Muralidharan","year":"2005","unstructured":"Muralidharan, G., Micalizzi, M., Speth, J., Raible, D. & Troy, S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 49, 220\u2013229. https:\/\/doi.org\/10.1128\/AAC.49.1.220-229.2005 (2005).","journal-title":"Antimicrob Agents Chemother"},{"key":"88048_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/jac\/dkp455","volume":"65","author":"M Parsonage","year":"2010","unstructured":"Parsonage, M. et al. Breakthrough bacteraemia with a susceptible Enterococcus faecalis during tigecycline monotherapy. J Antimicrob Chemother 65, 370\u2013374. https:\/\/doi.org\/10.1093\/jac\/dkp455 (2010).","journal-title":"J Antimicrob Chemother"},{"key":"88048_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/jac\/dkl441","volume":"59","author":"AY Peleg","year":"2007","unstructured":"Peleg, A. Y. et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59, 128\u2013131 (2007).","journal-title":"J Antimicrob Chemother"},{"key":"88048_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/cncr.24812","volume":"116","author":"G Rangaraj","year":"2010","unstructured":"Rangaraj, G., Granwehr, B. P., Jiang, Y., Hachem, R. & Raad, I. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 116, 967\u2013973. https:\/\/doi.org\/10.1002\/cncr.24812 (2010).","journal-title":"Cancer"},{"key":"88048_CR13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archinte.1962.03620240038007","volume":"110","author":"WR Mccabe","year":"1962","unstructured":"Mccabe, W. R. & Jackson, G. G. Gram-negative bacteremia: II. clinical, laboratory, and therapeutic observations. Arch Internal Med 110, 856\u2013864. https:\/\/doi.org\/10.1001\/archinte.1962.03620240038007 (1962).","journal-title":"Arch Internal Med"},{"key":"88048_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40, 373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8 (1987).","journal-title":"J Chronic Dis"},{"key":"88048_CR15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus, W. A., Draper, E. A., Wagner, D. P. & Zimmerman, J. E. APACHE II: a severity of disease classification system. Crit Care Med 13, 818\u2013829 (1985).","journal-title":"Crit Care Med"},{"key":"88048_CR16","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 32 edn, Vol. 42 (2019)."},{"key":"88048_CR17","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1128\/CMR.00062-05","volume":"19","author":"KK Hall","year":"2006","unstructured":"Hall, K. K. & Lyman, J. A. Updated review of blood culture contamination. Clin Microbiol Rev 19, 788\u2013802. https:\/\/doi.org\/10.1128\/CMR.00062-05 (2006).","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"88048_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1099\/00222615-46-6-517","volume":"46","author":"S Spanik","year":"1997","unstructured":"Spanik, S. et al. Risk factors, aetiology, therapy and outcome in 123 episodes of breakthrough bacteraemia and fungaemia during antimicrobial prophylaxis and therapy in cancer patients. J Med Microb 46(6), 517\u2013523 (1997).","journal-title":"J Med Microb"},{"issue":"2","key":"88048_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1365-2796.2005.01513.x","volume":"258","author":"M Lopez Dupla","year":"2005","unstructured":"Lopez Dupla, M. et al. Clinical characterization of breakthrough bacteraemia: a survey of 392 episodes. J Internal Med 258(2), 172\u2013180 (2005).","journal-title":"J Internal Med"},{"key":"88048_CR20","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/jac\/dkl403","volume":"58","author":"KA Rodvold","year":"2006","unstructured":"Rodvold, K. A. et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 58, 1221\u20131229 (2006).","journal-title":"J Antimicrob Chemother"},{"key":"88048_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/08998280.2006.11928154","volume":"19","author":"ND Greer","year":"2006","unstructured":"Greer, N. D. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 19, 155\u2013161. https:\/\/doi.org\/10.1080\/08998280.2006.11928154 (2006).","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"88048_CR22","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1086\/431675","volume":"41","author":"EJE Grosse","year":"2005","unstructured":"Grosse, E. J. E. et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41, S341\u2013S353 (2005).","journal-title":"Clin Infect Dis"},{"key":"88048_CR23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1086\/505494","volume":"43","author":"GE Stein","year":"2006","unstructured":"Stein, G. E. & Craig, W. A. Tigecycline: a critical analysis. Clin Infect Dis 43, 518\u2013524 (2006).","journal-title":"Clin Infect Dis"},{"key":"88048_CR24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas, P. G. et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 62, e1-50. https:\/\/doi.org\/10.1093\/cid\/civ933 (2016).","journal-title":"Clin Infect Dis"},{"key":"88048_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13613-020-00715-2","volume":"10","author":"G De Pascale","year":"2020","unstructured":"De Pascale, G. et al. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. Ann Intensive Care 10, 94. https:\/\/doi.org\/10.1186\/s13613-020-00715-2 (2020).","journal-title":"Ann Intensive Care"},{"key":"88048_CR26","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/cc13858","volume":"18","author":"G De Pascale","year":"2014","unstructured":"De Pascale, G. et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 18, R90. https:\/\/doi.org\/10.1186\/cc13858 (2014).","journal-title":"Crit Care"},{"key":"88048_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","author":"PD Tamma","year":"2024","unstructured":"Tamma, P. D. et al. Infectious diseases society of america 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis https:\/\/doi.org\/10.1093\/cid\/ciae403 (2024).","journal-title":"Clin Infect Dis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88048-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88048-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88048-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T16:08:36Z","timestamp":1738685316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88048-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["88048"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-88048-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"8 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4266"}}